Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Decitabine + Durvalumab for Head and Neck Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial will study the safety and efficacy of the combination of oral decitabine and durvalumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who have progressed during or after treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service